Could a cancer imaging agent spot hidden heart inflammation?

NCT ID NCT07159074

Recruiting now Diagnosis Sponsor: Duke University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is testing whether a radioactive tracer called Tc 99m tilmanocept, already used in other imaging, can help detect cardiac sarcoidosis—a condition where inflammation forms in the heart. Researchers will give the tracer to 15 adults with confirmed sarcoidosis and take special SPECT/CT pictures. They will compare these images to standard FDG-PET scans and MRI to see if the new method works as well or better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tc 99m tilmanocept (a radioactive tracer used for imaging)
What this could lead to: If successful, this could provide a new, more accurate way to diagnose cardiac sarcoidosis without the need for fasting or special preparation.
What could go wrong: This is a small early-phase study with only 15 participants, so results may not apply to everyone. The imaging agent is being repurposed, and its effectiveness for this specific condition is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC SARCOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiac sarcoidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC SARCOIDOSIS

Contacts and locations

Locations

Duke University Hospital
RECRUITING

Durham, North Carolina, 27710, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.